Bezuclastinib

Name: Bezuclastinib in Gastrointestinal stromal tumor: Pharmacodynamics
Published: 2026-09-14T15:39:06-04:00

Gastrointestinal stromal tumor

Manufacturer: Cogent Biosciences
Regulatory submission: NDA submitted April 2026
Launch: Anticipated in the second half of 2026
Last updated: September 19, 2026

Section

Product information and disease description Product description Product information Pharmacology

Pharmacodynamics

2 evidence topics · 3 sources

Preclinical xenograft evidence

“PLX9486 showed anti-tumor efficacy in patient-derived imatinib-resistant GIST xenograft models, mainly through inhibition of KIT signaling.” (opens the source at this quote in a new tab)

KIT resistance mechanisms and preclinical inhibitor testing

“drugs in clinical development that potently inhibit most KIT AP or AL mutations exhibit poor activity against AP/AL mutations” (opens the source at this quote in a new tab)